Granada Hills, California–(Newsfile Corp. – June 16, 2021) – Pervasip Corp. (OTC Pink: PVSP) (the “Company”) is pleased to announce that it has purchased a five percent (5%) non-dilutive interest in Kaiyon Biotech Inc. (“Kaiyon”).

Kaiyon is a collaboration of doctors, scientists, researchers and chemists that work to create new medicines using psilocybin and CBD compounds. The biotech team at Kaiyon believes that existing psilocybin research presents a pressing case for psilocybin to be an effective treatment for depression, pain, and drug addiction. It plans to expand on that research and support a hot bed of innovation for safe and productive drug use.

The Company applauds the newly formed Psilocybin Advisory Board formed in Oregon, and Oregon’s efforts to build a support infrastructure through which psilocybin can be introduced to daily living via therapeutic use and licensed facilities.

The Company intends to leverage doctors and trained professionals in South Korea via its ownership in Kaiyon and bring the experience and training back to the United States. The acquisition requires the Company to issue 50 million restricted shares of common stock.

About Pervasip Corp.

Pervasip Corp. is a developer of companies and technologies in high value emerging markets. Pervasip is currently pursuing the acquisition of Artizen Corporation, which generates revenues by providing leasing, licensing, management, staffing, and supplies to cannabis production facilities.

Please email Investor Relations with any questions at [email protected] or call 855-464-2535 extension 1.

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include those that use forward-looking terminology, such as the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “hope'” “project,” “plan,” “will,” “shall,” “should,” and similar expressions, including when used in the negative. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/87721